ClinicalTrials.gg
RecruitingNCT06260943Updated Nov 2, 2026

Targeted Navigation in Hepatocellular Carcinoma (HCC)

An interventional study of Target Navigation Pilot Program in Hepatocellular Carcinoma, Cholangiocarcinoma and Hepatobiliary Cancer, sponsored by University of Miami. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by University of Miami · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.
Updated Nov 2, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
210
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 926 studies in Carcinoma, Hepatocellular with a site in United States — 160 open to participants now, 245 under way, 17 of them phase 3. Carcinoma, Hepatocellular · United States.

Planned enrollment
107th of 775
210 · median 36
Started
2024
with 34 others
No phase
124 of 926
26 open now
Primary completion
2026-10
later than 58 of 244 live
Registered
831st of 926
by date

Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, this one is the 107th largest by planned enrollment of the 775 interventional ones that give a count, is one of 35 that started in 2024, is one of 124 with no phase, reaches primary completion later than 58 of the 244 other live ones, and was the 831st registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

160 of the 926 studies in Carcinoma, Hepatocellular with a site in United States are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 926 studies in Carcinoma, Hepatocellular with a site in United States, or all of them as a file.
02

Study summary

The investigators are trying to learn more about the personal perceptions and experiences regarding the needs of patients with liver cancer to help improve the care of all patients. The investigators would like to know whether there are needs that patients have or are aware of, especially those needs that the investigators have not been able to address. The investigators aim to develop a program that helps participants and participant's families to navigate the process of being diagnosed with liver cancer and receiving treatment.

03

Conditions studied

  • Hepatocellular Carcinoma
  • Cholangiocarcinoma
  • Hepatobiliary Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • HCC Patients:

    • Enrolled or eligible for enrollment in Unified Prospective Registry and Biorepository of Patients with Chronic Liver Disease or Hepatobiliary Cancers Including Hepatocellular Carcinoma (HCC) and Cholangiocarcinoma.
    • Diagnosis of hepatocellular carcinoma, confirmed by clinical chart review and International Classification of Diseases, Tenth Revision (ICD-10) C22.0.
    • Adults, age 18 or older
    • Able to provide
  • All other interviewees:

    • Advocates who will self-identify as having had HCC.
    • Others who self-identify as either a caregiver or support person of an HCC patient.

Physicians/Licensed Independent Practitioners, Social Workers, Nurse Navigators, and Research Coordinators will all self-identify as being involved in the care of HCC patients.

Exclusion criteria

Exclusion Criteria:

  • Unable to speak Spanish or English
  • West Haven Grade 2 or higher hepatic encephalopathy19 or other cognitive impairment.
  • Adults unable or unwilling to consent
  • Individuals who are not yet adults (infants, children, teenagers)
  • Prisoners
  • Given that this study is minimal risk and there are no risks to a potential fetus, investigators will not exclude pregnant women; however, no data about pregnancy or their fetus is being collected
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    Aim 3: Targeted Navigation Pilot Program

    Participants in this group will be enrolled in a Targeted Navigation Pilot Program for up to 12 months.

    Behavioral: Target Navigation Pilot Program

Interventions

  • BehavioralTarget Navigation Pilot Program

    Participants will meet with a navigator, in either English, Spanish or Creole, biweekly, in person or virtually, until the first treatment appointment and every three months after. Each session will last approximately one hour; depending on the needs identified, patients will be connected to appropriate institutional or community-based resources.

06

What researchers measure

Primary outcomes

  1. Number of Hours for Each Contact

    The length of time of each contact will be assessed in number of hours. Contact is defined as the length of time the navigator meets with the participant.

    Time frame: Up to 12 months

  2. Number of Months of Total Navigation

    The length of total navigation will be assessed in number of months.

    Time frame: Up to 12 months

  3. Acceptability

    Percentage of approached individuals who agree to participate

    Time frame: Enrollment

Secondary outcomes

  1. Number of Days to First Contact

    The time to first contact since hepatocellular carcinoma diagnosis will be assessed in number of days.

    Time frame: Up to 12 months

  2. Number of Participants that Die Within One Year

    Number of participants that die within one year of enrollment in the navigation program.

    Time frame: Up to 1 year

  3. Number of Days to First Treatment

    The time to first treatment will be assessed in number of days.

    Time frame: Up to 12 months

  4. Proportion of Participants Enrolled in Clinical Research

    The proportion of participants enrolled in clinical research will be reported.

    Time frame: Up to 12 months

Other outcomes

  1. Number of Days to First Appointment

    The time to first appointment will be assessed in number of days.

    Time frame: Up to 12 months

  2. Retention Rate

    The number of participants still engaged in the program divided by the number still living

    Time frame: From enrollment to the three months assessment

  3. Feasibility of completing assessment

    The proportion of participants completing the baseline assessment

    Time frame: From enrollment at baseline to 30 days post enrollment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Oct 2026, 30 months.

Of 361 non-industry interventional studies with no phase under Carcinoma, Hepatocellular, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's 30 months is below that.

Counting every sponsor, half of 385 studies reached it within 47 months; a quarter within 23 and three quarters within 75.

Completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jul 2027, on Nov 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2024
First posted
Feb 15, 2024
StartActual
Apr 15, 2024
Primary completionActual
Oct 15, 2026
CompletionEst.
Jul 31, 2027was Oct 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 31, 2026→Oct 15, 2026 (actual)
Nov 2, 2026
Study completion
Oct 31, 2026→Jul 31, 2027
Nov 2, 2026
Eligibility
Revised
Nov 2, 2026
Primary outcomes
4 removed
What changed in the outcomes
  • RemovedNumber of Days to First ContactTime frame: Up to 12 months
  • RemovedNumber of Days to First TreatmentTime frame: Up to 12 months
  • RemovedNumber of Participants that Die Within One YearTime frame: Up to 1 year
  • RemovedProportion of Participants Enrolled in Clinical ResearchTime frame: Up to 12 months
Nov 2, 2026
Secondary outcomes
4 added
What changed in the outcomes
  • AddedNumber of Days to First ContactTime frame: Up to 12 months
  • AddedNumber of Participants that Die Within One YearTime frame: Up to 1 year
  • AddedNumber of Days to First TreatmentTime frame: Up to 12 months
  • AddedProportion of Participants Enrolled in Clinical ResearchTime frame: Up to 12 months
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Primary completion Oct 31, 2026→Oct 15, 2026 (now actual)
    Study completion Oct 31, 2026→Jul 31, 2027
    Eligibility Revised
    Primary outcomes 4 removed
    What changed in the outcomes
    • RemovedNumber of Days to First ContactTime frame: Up to 12 months
    • RemovedNumber of Days to First TreatmentTime frame: Up to 12 months
    • RemovedNumber of Participants that Die Within One YearTime frame: Up to 1 year
    • RemovedProportion of Participants Enrolled in Clinical ResearchTime frame: Up to 12 months
    Secondary outcomes 4 added
    What changed in the outcomes
    • AddedNumber of Days to First ContactTime frame: Up to 12 months
    • AddedNumber of Participants that Die Within One YearTime frame: Up to 1 year
    • AddedNumber of Days to First TreatmentTime frame: Up to 12 months
    • AddedProportion of Participants Enrolled in Clinical ResearchTime frame: Up to 12 months
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06260943
Collaborators
The V Foundation
Responsible party
Patricia Jones, MD (Associate Professor of Clinical Medicine, University of Miami) — Principal investigator
First posted
Feb 15, 2024
Start date
Apr 15, 2024
Primary completion
Oct 15, 2026
Completion
Jul 31, 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Gloria Figueroa
Contact
gef44@med.miami.edu
(305) 243-0779
Patricia Jones, MD
Contact
pdjones@med.miami.edu
(305) 243-0779
Patricia Jones, MD
principal investigator · University of Miami

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion